search
Back to results

Bioboosti Device for Insomnia Treatment

Primary Purpose

Insomnia

Status
Enrolling by invitation
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Bioboosti
Sponsored by
Brigham and Women's Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Insomnia focused on measuring insomnia, sleep, Bioboosti, Biomobie, device

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with insomnia

Exclusion Criteria:

  • Untreated moderate or severe sleep apnea
  • Major circadian rhythm disorder
  • Pregnant women
  • Breastfeeding
  • Cardiac pacemaker
  • Cancer
  • Severe conditions related to heart, brain, kidney and hematopoietic system
  • Severe/unstable angina pectoris
  • Arteria coronaria/ peripheral arterial bypass graft
  • Acute congestive heart failure
  • Renal insufficiency
  • Mechanical intestinal obstruction
  • Any electrical devices

Sites / Locations

  • Brigham and Women's Hospital
  • Brigham and Women's Faulkner Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Bioboosti

Sustained Efficacy

Insomnia and migraine

Arm Description

Treatment with the Bioboosti device for two weeks. The device produces a pulsed micro-magnetic field. Subjects will use it once a day for about one hour, before habitual sleep time.

Treatment with Bioboosti device for a year. In order to see if the device has sustained efficacy in treating insomnia. Subjects will use it once a day for about one hour, before habitual sleep time.

Treatment with the Bioboosti device for a month. Subjects will use it once a day for about one hour, before habitual sleep time.

Outcomes

Primary Outcome Measures

Change in Insomnia symptoms before treatment to after treatment
Within subject comparisons before and after treatment, subjects answer questions on their sleep habits.
Change in Sleepiness before treatment to after treatment
Within subject comparisons before and after treatment, subjects answer questions on sleep difficulty.

Secondary Outcome Measures

Change in EEG from before treatment to after treatment
Ambulatory EEG will be used before treatment and after treatment, using sleep montage per standard AASM criteria and scored by a registered polysomnography technologist using AASM guidelines. Sleep architecture will be reported as the percent of time the subject remains in the different sleep stages. Specifically we will compare percent in REM sleep before and after treatment. The waveform of the EEG that will be assessed during teh study period is delta.

Full Information

First Posted
September 20, 2016
Last Updated
July 27, 2023
Sponsor
Brigham and Women's Hospital
Collaborators
Biomobie, Harvard University
search

1. Study Identification

Unique Protocol Identification Number
NCT02924116
Brief Title
Bioboosti Device for Insomnia Treatment
Official Title
Use of Bioboosti Non-pharmacologic Device for Insomnia Treatment: A Pilot Study
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Enrolling by invitation
Study Start Date
September 2016 (undefined)
Primary Completion Date
June 2024 (Anticipated)
Study Completion Date
December 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Brigham and Women's Hospital
Collaborators
Biomobie, Harvard University

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine the effects of the Bioboosti device on sleep for patients who have been diagnosed with insomnia.
Detailed Description
Insomnia is a common health complaint that is associated with discomfort, loss of productivity, poor health and higher use of healthcare. The use of non-pharmacologic treatments for insomnia has gained much attention in recent years. The investigators are conducting this research because a safe, non-pharmacologic treatment would benefit patients with insomnia, and to see if the Bioboosti device is an effective treatment for insomnia. Subjects will include patients from the clinics who have the diagnosis of insomnia. Study staff will notify the treating physician of a potential subject. If the subject gives permission and would like to obtain more information, study staff will approach them and provide them with the consent form to review. Study staff may also contact them by phone to explain the study and recruit. Subjects will be asked to make 5 visits: Visit 1-- consent form, physical exam, vitals, pregnancy test, sleep log Visit 2-- sleep questionnaires, urine test for hormones associated with sleep, sleep log, placement of EEG Visit 3-- remove EEG, beginning of treatment with Bioboosti device, sleep log Treatment phase-- subjects use the Bioboosti at home for two weeks Visit 4-- return of Bioboosti, sleep questionnaires, urine test for hormones associated with sleep, sleep log, placement of EEG Visit 5-- remove EEG, collect sleep logs

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Insomnia
Keywords
insomnia, sleep, Bioboosti, Biomobie, device

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Model Description
Subjects will complete the first arm of the study. Upon completion, the subjects will be offered enrollment into the next long term arm of the study (Sustained Efficacy).
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
21 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Bioboosti
Arm Type
Experimental
Arm Description
Treatment with the Bioboosti device for two weeks. The device produces a pulsed micro-magnetic field. Subjects will use it once a day for about one hour, before habitual sleep time.
Arm Title
Sustained Efficacy
Arm Type
Experimental
Arm Description
Treatment with Bioboosti device for a year. In order to see if the device has sustained efficacy in treating insomnia. Subjects will use it once a day for about one hour, before habitual sleep time.
Arm Title
Insomnia and migraine
Arm Type
Experimental
Arm Description
Treatment with the Bioboosti device for a month. Subjects will use it once a day for about one hour, before habitual sleep time.
Intervention Type
Device
Intervention Name(s)
Bioboosti
Intervention Description
Subjects will place the device on the palm of their hand for 8 minutes. There is a light on the device that changes to indicate that the 8 minutes have passed. They will then place it on the palm of the other hand and keep it there for 8 minutes. Alternating 8-minute cycles between hands will be done up to 6 times.
Primary Outcome Measure Information:
Title
Change in Insomnia symptoms before treatment to after treatment
Description
Within subject comparisons before and after treatment, subjects answer questions on their sleep habits.
Time Frame
Week 1, Week 4
Title
Change in Sleepiness before treatment to after treatment
Description
Within subject comparisons before and after treatment, subjects answer questions on sleep difficulty.
Time Frame
Week 1, Week 4
Secondary Outcome Measure Information:
Title
Change in EEG from before treatment to after treatment
Description
Ambulatory EEG will be used before treatment and after treatment, using sleep montage per standard AASM criteria and scored by a registered polysomnography technologist using AASM guidelines. Sleep architecture will be reported as the percent of time the subject remains in the different sleep stages. Specifically we will compare percent in REM sleep before and after treatment. The waveform of the EEG that will be assessed during teh study period is delta.
Time Frame
Week 2, Week 4

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with insomnia Exclusion Criteria: Untreated moderate or severe sleep apnea Major circadian rhythm disorder Pregnant women Breastfeeding Cardiac pacemaker Cancer Severe conditions related to heart, brain, kidney and hematopoietic system Severe/unstable angina pectoris Arteria coronaria/ peripheral arterial bypass graft Acute congestive heart failure Renal insufficiency Mechanical intestinal obstruction Any electrical devices
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Milena Pavlova, MD
Organizational Affiliation
Brigham and Women's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Brigham and Women's Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Facility Name
Brigham and Women's Faulkner Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02130
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Bioboosti Device for Insomnia Treatment

We'll reach out to this number within 24 hrs